Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves th… Read more
Tianjin Chase Sun Pharmaceutical Co Ltd - Asset Resilience Ratio
Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has an Asset Resilience Ratio of -0.89% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2023)
This chart shows how Tianjin Chase Sun Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Chase Sun Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-105.72 Million | -0.89% |
| Total Liquid Assets | CN¥-105.72 Million | -0.89% |
Asset Resilience Insights
- Limited Liquidity: Tianjin Chase Sun Pharmaceutical Co Ltd maintains only -0.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Tianjin Chase Sun Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tianjin Chase Sun Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2023)
The table below shows the annual Asset Resilience Ratio data for Tianjin Chase Sun Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.89% | CN¥-105.72 Million | CN¥11.84 Billion | +0.36pp |
| 2022-12-31 | -1.25% | CN¥-158.00 Million | CN¥12.63 Billion | +0.33pp |
| 2021-12-31 | -1.58% | CN¥-183.67 Million | CN¥11.61 Billion | +0.20pp |
| 2020-12-31 | -1.78% | CN¥-181.52 Million | CN¥10.18 Billion | -1.09pp |
| 2019-12-31 | -0.69% | CN¥-58.31 Million | CN¥8.43 Billion | -0.28pp |
| 2018-12-31 | -0.41% | CN¥-30.99 Million | CN¥7.48 Billion | -0.53pp |
| 2006-12-31 | 0.12% | CN¥124.36K | CN¥105.62 Million | -- |